Select Location
We need your delivery location to continue browsing
Prescription Required
janssen biotech
90 capsules
Ibrutinib
Keep in cold place
Delivering To:
Overview
Imbruvica 140mg Capsule is classified as an anticancer medication. Mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (MZL) are among the blood cancers that are mainly treated with this medication. In the human body, cancer cell development is uncontrolled and abnormal. Early cancer diagnosis is a challenging task. Only the disease's symptoms can be reduced when it is discovered in its advanced stages. Ibrutinib is the active ingredient in Imbruvica 140mg Capsule.
Chronic lymphocytic leukemia, lymphocytic lymphoma
The Imbruvica 140 mg uses include: To treat mantle cell lymphoma
In the treatment of chronic lymphocytic leukaemia (Blood cancer) to treat small lymphocytic lymphoma
In the treatment of Waldenstrom’s macroglobulinemia
To treat chronic graft vs. host disease after failure of systemic therapy
The human body shows undesired symptoms after taking Imburuvica 140mg Tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Some of the common side effects of Imburuvica Tablet are mentioned below:
High risk of infection
Vomiting
Weakness
Nausea
Fatigue
Fever
Decreased blood cells (red cells, white cells, and platelets), Diarrhea cough
Imburuvica 140mg Tablet is a prescription-based anticancer drug. It is advised to take this tablet after consulting your healthcare expert. This medicine should be taken at the same time every day for better results.
An inhibitor of Bruton's tyrosine kinase is imbruvica 140mg capsule. Inhibiting BTK signaling delays the onset of the disease, inhibits the cancer cells, and encourages apoptosis, or programmed cell death. This focused strategy lowers the burden of tumors, enhances overall survival rates, and improves patient outcomes. When taken orally, imbruvica offers long-term, sustained disease control and is a safer option than normal chemotherapy.
Alcohol
consult your doctor
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Imburuvica 140mg Tablet. It is advised to consult your doctor for further information.
Pregnancy
consult your doctor
Imburuvica 140mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such condition.
Breast Feeding
consult your doctor
Imburuvica 140mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor.
Driving
unsafe
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Imburuvica 140mg Tablet.
Kidney
safe if prescribed
Share your medical history with your healthcare expert in case of kidney disease before taking Imburuvica 140mg Tablet.
Liver
safe if prescribed
Inform your doctor before starting Imburuvica 140mg Tablet if you have liver disease to avoid any serious side effects.
It is advised not to miss any scheduled dosage of Imburuvica 140mg Tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.
No, children below 18 years of age are not advised to take this medicine as it results in severe complications.
No, it is advised to avoid taking this medicine if you have serious kidney problems. Consult the doctor before taking this medication.
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Imburuvica 140mg Tablet.
No, it is recommended to avoid taking this injection if the person has anemia or any blood-related disorder.
It is not safe to use this medicine during pregnancy as it causes harmful effects on the developing baby.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Chen, L.S et al., (2018). A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood, 132(21), 2249–2259.
Davids, M. S., & Brown, J. R. (2024). Ibrutinib: A first-in-class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncology, 10(6), 957–967. Bioequivalence study of Binap® (ibrutinib 140 mg) vs. Imbruvica®. (2024). Journal of Hematology.
Janssen Research & Development, LLC. (2024). Study to assess the bioequivalence of ibrutinib 140 mg tablet to 140 mg IMBRUVICA capsule (NCT02877225). ClinicalTrials.gov.
Li, S., Young, K. H., & Medeiros, L. J. (2024). [Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL]. Blood Advances, 8(4), 832–841.
Ryan, C. (2025). FDA approves generic ibrutinib tablets for B‑cell malignancies. OncLive.